238 related articles for article (PubMed ID: 19191252)
1. Beneficiary price sensitivity in the Medicare prescription drug plan market.
Frakt AB; Pizer SD
Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
[TBL] [Abstract][Full Text] [Related]
2. Attribute substitution in early enrollment decisions into Medicare prescription drug plans.
Frakt AB; Pizer SD
Health Econ; 2008 Apr; 17(4):513-21. PubMed ID: 17935198
[TBL] [Abstract][Full Text] [Related]
3. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
4. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
5. Predicting risk selection following major changes in Medicare.
Pizer SD; Frakt AB; Feldman R
Health Econ; 2008 Apr; 17(4):453-68. PubMed ID: 17557273
[TBL] [Abstract][Full Text] [Related]
6. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
7. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
Walberg MP; Patel RA
J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
[TBL] [Abstract][Full Text] [Related]
8. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
9. Should Medicare adopt the Veterans Health Administration formulary?
Frakt AB; Pizer SD; Feldman R
Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
[TBL] [Abstract][Full Text] [Related]
10. Analysis of national annual variation in total patient out-of-pocket Medicare Part D stand-alone prescription drug plan costs from 2007 to 2008.
Walberg MP; Patel RA; Amaral MM
J Med Econ; 2008; 11(4):625-37. PubMed ID: 19450072
[TBL] [Abstract][Full Text] [Related]
11. Part D plan enrollment by uninsured medicare beneficiaries.
Maciejewski ML; Farley JF; Hansen RA; Wei D; Harman JS
Med Care; 2010 Feb; 48(2):183-6. PubMed ID: 20057332
[TBL] [Abstract][Full Text] [Related]
12. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
Cubanski J; Neuman P
Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: Medicare Part D.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
[No Abstract] [Full Text] [Related]
15. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
[TBL] [Abstract][Full Text] [Related]
16. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
17. Adverse selection in the Medicare prescription drug program.
Riley GF; Levy JM; Montgomery MA
Health Aff (Millwood); 2009; 28(6):1826-37. PubMed ID: 19887424
[TBL] [Abstract][Full Text] [Related]
18. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
Jackson EA; Axelsen KJ
Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
[TBL] [Abstract][Full Text] [Related]
19. Drug plan design incentives among Medicare prescription drug plans.
Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
[TBL] [Abstract][Full Text] [Related]
20. Price stability. No hike expected in Medicare drug plan averages.
Zigmond J
Mod Healthc; 2011 Aug; 41(32):11. PubMed ID: 21879693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
